PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancerYin Min Thu(Okayama University), Shinichi Toyooka(Okayama University)PLoS ONEMay 17, 202410.1371/journal.pone.0300644Cited by 9SaveCiteExport RISWatch citationsRelated PapersImmune evasion through mitochondrial transfer in the tumour microenvironment|Nature|2025|239Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features|Scientific Reports|2017|60Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer|PLoS ONE|2017|41Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer|Oncology Letters|2017|28Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer|PLoS ONE|2014|27